Status:
TERMINATED
Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
Lead Sponsor:
New Mexico Cancer Research Alliance
Collaborating Sponsors:
Genentech, Inc.
Conditions:
Carcinoma, Non-Small-Cell Lung
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
This study was conducted to compare the activities of erlotinib to that of intravenous, platinum-based therapy in the treatment of non-small cell lung cancer (NSCLC). The goal of this trial was to dem...
Detailed Description
To compare the activities (the progression-free survival, the incidence and severity of toxicities, and reversibility of toxicities) of erlotinib to that of platinum-based therapy in NSCLC. A sequenti...
Eligibility Criteria
Inclusion
- Prior chemotherapy will be allowed for other invasive malignancies, provided at least five years has elapsed since the completion of therapy and enrollment on this protocol. No prior chemotherapy for metastatic non-small cell lung cancer (NSCLC) will be allowed. Prior adjuvant or neoadjuvant chemotherapy for NSCLC will be allowed, provided at least six months have elapsed from the last dose of chemotherapy to the documentation of relapsed disease.
- Baseline laboratory values (bone marrow, renal, hepatic):
- Adequate bone marrow function:
- Absolute neutrophil count \>1000/µL
- Platelet count \>100'000/µL
- Renal function:
- Serum creatinine \< 2.0 mg %
- Hepatic function:
- Bilirubin \<1.5x normal
- Serum calcium \< 12 mg/dl
- Other Eligibility Criteria:
- Signed Informed Consent
- Eastern Cooperative Oncology Group (ECOG)/Zubrod/Southwest Oncology Group (SWOG) Performance Status \<2 (Karnofsky Performance Status \> 70%)
- Life expectancy \> 8 weeks
- Male or female' age \>18 years
- Patients of childbearing potential must be using an effective means of contraception.
- Histologic diagnosis of NSCLC that is advanced and cannot be treated adequately by radiotherapy or surgery; or metastatic disease
Exclusion
- Prior therapy with an epidermal growth factor receptor inhibitor, including erlotinib, gefitinib, and cetuximab, as well as any investigational HER-1 inhibiting agent
- Pregnant or lactating females
- Myocardial infarction or ischemia within the 6 months before Cycle 0' Day 0
- Uncontrolled' clinically significant dysrhythmia
- History of prior malignancy within the prior five years, with the exception of non-melanoma carcinomas of the skin, and carcinoma in situ of the cervix
- Prior radiotherapy to an indicator lesion unless there is objective evidence of tumor growth in that lesion
- Uncontrolled metastatic disease of the central nervous system (previously treated, stable disease is allowable on this protocol)
- Radiotherapy within the 2 weeks before Cycle 1' Day 1
- Surgery within the 2 weeks before Cycle 1' Day 1
- Any co morbid condition that' in the view of the attending physician' renders the patient at high risk from treatment complications
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2012
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT00391586
Start Date
July 1 2006
End Date
May 1 2012
Last Update
August 17 2015
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Lovelace Medical Group
Albuquerque, New Mexico, United States, 87102
2
Hematology Oncology Associates NM
Albuquerque, New Mexico, United States, 87106
3
Presbyterian Medical Group
Albuquerque, New Mexico, United States, 87110
4
University of New Mexico Cancer Center
Albuquerque, New Mexico, United States, 87131